Latest News and Press Releases

MELBOURNE, Australia, June 01, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that it has received...

MELBOURNE, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) (‘Cynata’) is pleased to announce a A$5.2 million...

MELBOURNE, Australia, May 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the final patient has...

Initial data from preclinical study at the University of Massachusetts Amherst demonstrate Cymerus MSCs ameliorate the effects of cytokine release syndrome (CRS) and other related adverse reactions to...

MELBOURNE, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that it has been...

MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States...

MELBOURNE, Australia, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary...

MELBOURNE, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that the first patient...

MoU signed with Celularity, Inc. for the evaluation of and identification of commercial opportunities for the CymerusTM platform and Celularity’s leading cell therapy assetsFollows...

MELBOURNE, Australia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the independent Data...